


Effective 10/01/2004. Patent fees are subject to annual revision.		Complete if Known	
FEE TRANSMITTAL For FY 2005		Application Number	10/023,584-Conf. #4809
		Filing Date	December 21, 2001
		First Named Inventor	Craig A. Rosen
		Examiner Name	R. S. Landsman
		Art Unit	1647
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27	Attorney Docket No.	PF112P1D2	
TOTAL AMOUNT OF PAYMENT	(\$) 0.00		

METHOD OF PAYMENT (check all that apply)		FEE CALCULATION (continued)			
<input type="checkbox"/> Check	<input type="checkbox"/> Credit Card	2. EXTRA CLAIM FEES			
<input checked="" type="checkbox"/> Deposit Account	<input type="checkbox"/> Money Order				
	<input type="checkbox"/> None				
Deposit Account Number	08-3425				
Deposit Account Name	Human Genome Sciences, Inc.				
The Director is hereby authorized to: (check all that apply)					
<input type="checkbox"/> Charge fee(s) indicated below					
<input type="checkbox"/> Charge fee(s) indicated below, except for the filing fee					
<input checked="" type="checkbox"/> Charge any additional fee(s) or any underpayment of fee(s) under 37 CFR 1.16 and 1.17					
<input checked="" type="checkbox"/> Credit any overpayments					
To the above-identified deposit account.					
<input type="checkbox"/> Other (please identify):					
FEE CALCULATION					
1. BASIC FILING FEE					
Fee Description	Fee (\$)	Small Entity Fee (\$)	Fee Paid (\$)		
Utility Filing Fee	790	395			
Design Filing Fee	350	175			
Plant Filing Fee	550	275			
Reissue Filing Fee	790	395			
Provisional Filing Fee	160	80			
Subtotal (1) \$					
		3. OTHER FEES			
		Fee Description	Fee (\$)	Small Entity Fee (\$)	Fee Paid
		1-month extension of time	110	55	
		2-month extension of time	430	215	
		3-month extension of time	980	490	
		4-month extension of time	1,530	765	
		5-month extension of time	2,080	1,040	
		Information disclosure stmt. Fee	180	180	
		37 CFR 1.17(q) processing fee	50	50	
		Non-English specification	130	130	
		Notice of Appeal	340	170	
		Filing a brief in support of appeal	340	170	
		Request for oral hearing	300	150	
		Other:			
Subtotal (2) \$					
Subtotal (3) \$					

SUBMITTED BY			
Signature		Registration No. (Attorney/Agent)	41,512
Name (Print/Type)	Melissa J. Pytel	Telephone	(301) 610-5764
		Date	Dec. 7, 2004



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Rosen et al.

Docket No.: PF112P1D2

Application No.: 10/023,584

Confirmation No.: 4809

Filed: December 21, 2001

Art Unit: 1647

For: Antibodies to Human Vascular Endothelial
Growth Factor 2 (as amended)

Examiner: R. S. Landsman

**EIGHTH SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorney for Applicants hereby directs the Examiner's attention to references GL and GM listed on the attached Form PTO/SB/08. Copies of the references are enclosed.

Identification of the listed references is not to be construed as an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to take appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 CFR 1.104(a) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be considered during the prosecution of this application.

Applicants respectfully request that the Examiner review the listed references and that the references be made of record in the file history of the application.


Pursuant to 37 C.F.R. § 1.97(c), since this Information Disclosure Statement is being filed after the mailing date of a first Office Action on the merits, but before the mailing date of a Final Office Action, or a Notice of Allowance under 37 C.F.R. § 1.311, or an action that otherwise closes prosecution, the Patent and Trademark Office will consider this Information Disclosure Statement if it is accompanied by a statement as specified in 37 C.F.R. § 1.97(e) or the fee as specified in 37 C.F.R. § 1.17(p).

Accordingly, the undersigned certifies pursuant to 37 C.F.R. § 1.97(e)(1) that reference GL contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of this Information Disclosure Statement. Further, pursuant to 37 C.F.R. § 1.704(d), the undersigned certifies that reference GL contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart application, and that this communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of this Information Disclosure Statement. In particular, the reference was cited in a Supplementary Partial European Search Report (reference GM) dated November 8, 2004, in connection with corresponding international application.

Applicants believe that no fee is due in connection with this submission. However, should the Patent Office determine otherwise, please charge such fee to our Deposit Account No. 08-3425.

Dated: Dec 7, 2004

Respectfully submitted,

By 

Melissa J. Pytel

Registration No.: 41,512
HUMAN GENOME SCIENCES, INC.
14200 Shady Grove Road
Rockville, Maryland 20850
(301) 610-5764

MMW/MJP/ba



PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/023,584-Conf. #4809
				Filing Date	December 21, 2001
				First Named Inventor	Craig A. Rosen
				Art Unit	1647
				Examiner Name	R. S. Landsman
Sheet	1	of	1	Attorney Docket Number	PF112P1P1D2

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	GL	WO-95/24473	09-14-1995	Human Genome Sciences, Inc.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	GM	Supplementary European Search Report, Application No. EP 00 90 5992, mailed November 8, 2004.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--